The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Harrow, Inc. (NASDAQ:HROW) stock is a name we have previously identified for speculative trades. Both instances, here and here, have been profitable trades. In the near to even medium term, we view it ...

Shares of ophthalmology concern Harrow, Inc. (HROW) are down over 50% since posting a below consensus Q3 2024 financial report in November 2024, as sales were only up 1% sequentially. An inventory ...

Harrow Announces Positive Results From Prospective Randomized Contralateral-Eye Study Evaluating IHEEZO Ophthalmic Gel In Patients Undergoing Same-Day Bilateral Intravitreal Injections CI Aug. 20 Harr ...

Harrow Inc (NASDAQ:HROW) and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement on Monday. Harrow acquired the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionate ...

Investors considering a purchase of Harrow Inc (Symbol: HROW) shares, but tentative about paying the going market price of $32.54/share, might benefit from considering selling puts among the ...

Harrow Inc. HROW shares are down during Tuesday’s premarket session as the company faces scrutiny following its recent financial results announcement. The eye disease medicine maker, Harrow, reported ...

The most immediate catalyst for Harrow Inc. stock is the noted gap between market price and GF Value, which widened after the shares fell 3.2 percent to USD 33.09 on September 17, 2026. GuruFocus ...

(RTTNews) - Harrow, Inc. (HROW), an eyecare pharmaceutical company, reported fourth-quarter results with a slip in net income despite 33% higher revenue, hurt by operating and income tax expenses. In ...